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Introduction
Metronidazole is considered first-line therapy for
patients with mild to moderate Clostridium difficile
infection (CDI), but was recently shown to be inferior to
vancomycin for clinical cure. The effect of treatment
choice on downstream outcomes such as recurrence and
risk of death is not well understood.
Objectives
To evaluate the impact of vancomycin or metronidazole
on CDI recurrence and 30-day mortality.
Methods
A retrospective cohort study of patients with CDI who
were treated with vancomycin or metronidazole in the US
Department of Veterans Affairs healthcare system between
1 January 2005 and 31 December 2012. A diagnosis of
CDI was based on a positive enzyme immunoassay or
cytotoxin test. CDI treatment was defined as administra-
tion or dispensing of vancomycin (oral or compounded)
or metronidazole (oral or intravenous) within two days
before or after the positive CDI result. Each patient treated
with vancomycin was matched with up to four patients
treated with metronidazole on propensity score, which
included comorbidity, utilization, and diagnosis of CDI in
the ICU as a proxy for disease severity. Patients were fol-
lowed for recurrence within 8 weeks and for mortality at
30 days after infection.
Results
There were 2,104 CDI patients treated with vancomy-
cin matched with 8,014 CDI patients treated with
metronidazole. Overall, 1,674 (16.5%) patients experi-
enced a recurrence and 1,177 (11.6%) of patients died
within 30 days. There was no difference in the risk of
recurrence by treatment group (15.8% vs. 16.7% for
vancomycin and metronidazole, p=0.32), but fewer
patients who received vancomycin died (8.6% vs.
12.4%, RR 0.69, 95% CI 0.59 – 0.80).
Conclusion
Recurrence rates were similar between treatment groups,
but the risk of 30-day mortality was significantly reduced
among patients who received vancomycin. The choice of
treatment for CDI has become increasingly complex with
the number of options available, and evidence regarding
clinical cure, recurrence, mortality, and cost must all be
taken into consideration. If validated, our observation that
vancomycin results in a lower mortality rate may justify
the additional costs of treatment relative to metronidazole.
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